Myovant Sciences is dedicated to developing innovative new products to treat diseases specific to women, including uterine fibroids, endometriosis and female infertility, as well as develop novel treatments for prostate cancer.
Uterine fibroids are non-cancerous tumors that develop from the muscle and connective tissue of the uterus. Approximately 25% of women of reproductive age have uterine fibroids, and 1 in 4 experience symptoms requiring treatment. Although uterine fibroids are benign tumors, they may cause debilitating symptoms including heavy and prolonged menstrual bleeding, anemia, and pelvic pain. Current treatments include hormonal contraceptives, GnRH agonists, and surgical interventions including myomectomy and hysterectomy.
Endometriosis is a gynecological medical condition in which cells that normally line the uterus grow outside of the uterine cavity. An estimated 7.5 million women in the United States have endometriosis, and 3 in 4 experience symptoms requiring treatment. During the menstrual cycle, endometriosis lesions grow, differentiate and shed into the abdomen, causing symptoms including non-menstrual pelvic pain and pain during menstruation (dysmenorrhea). Current treatments include hormonal contraceptives, danazol, GnRH agonists, and various surgical interventions for severe cases.
Prostate cancer is a malignant transformation of tissue within the male prostate gland. Often characterized by slow growth, prostate cancer is the second most prevalent form of cancer in men and the second leading cause of death due to cancer in men in the United States. Approximately 2.9 million men in the United States are currently living with prostate cancer, and 165,000 men are newly diagnosed each year. Symptoms of prostate cancer include increased urinary frequency, dysuria, hematuria and nocturnal urination. Current treatments include combinations of surgery, radiation or proton beam therapy, androgen deprivation therapy, and chemotherapy.
Approximately 25% of infertile women have problems related to ovulation, including the inability to produce fully matured eggs or release an egg from the ovary (i.e., "ovulate"). Fertility specialists use a group of medications, including GnRH agonists, to temporarily correct ovulatory problems and increase a woman's chance for pregnancy. These and related procedures are broadly termed Assisted Reproductive Technology, or ART. Approximately 1.6 million cycles of ART were performed globally in 2012.
To learn more about Myovant’s clinical trials, please visit www.clinicaltrials.gov. To learn more about those trials that are still enrolling, please visit www.myspiritstudy.com (for pain associated with endometriosis).